生命科学仪器2023，Vol.21Issue(3)：113-116,4.DOI:10.11967/2023210620
替米沙坦联合阿托伐他汀治疗老年早期DN患者的近远期疗效及对C反应蛋白、cysC的影响
Short-term and long-term efficacy of Telmisartan combined with atorvastatin in the treatment of elderly patients with early DN and their influence on C-reactive protein and cysC
摘要
Abstract
Objective:To investigate the short-term and long-term efficacy of telmisartan combined with atorvas-tatin in the treatment of elderly patients with early Diabetic nephropathy(DN)and the influence of telmisartan on C-reactive protein(CRP)and Cystatin C(Cysc).Methods:138 elderly patients with early DN who were treated in our hospital from August 2020 to August 2022 were divided into control group(n= 69)and observation group(n= 69)according to random number table method.Control group was treated with atorvastatin and insulin to control blood sugar.Observation group was given telmisartan in addition to control group.After continuous treatment for 3 months,short-term efficacy and changes in serum CRP and cysC levels were evaluated.After treatment,progress of DN was recorded during a six-month follow-up.Results:After continuous treatment for 3 months,there was a statistically significant difference between control group and observation group(P＜0.05).Total effective rate of ob-servation group was higher than that of control group(P＜0.05).Levels of serum CRP and cysC in observation group were lower than those in control group(P＜0.05).Within 3 months of treatment,there was no significant difference in the occurrence of new drug-related adverse reactions between control group and observation group(P＞0.05).Rate of DN progression in observation group was lower than that in control group(P＜0.05).Conclusion:Telmisartan combines with atorvastatin has good short-term and long-term efficacy in the treatment of elderly patients with early DN,which can significantly reduce the levels of CRP and cysC,drug is safe.关键词
早期糖尿病肾病/替米沙坦/阿托伐他汀/疗效/C反应蛋白/cysCKey words
Early diabetic nephropathy/Telmisartan/Atorvastatin/curative effect/C-reactive protein/cysC分类
医药卫生引用本文复制引用
于军威,王巨阁,韩进军..替米沙坦联合阿托伐他汀治疗老年早期DN患者的近远期疗效及对C反应蛋白、cysC的影响[J].生命科学仪器,2023,21(3):113-116,4.基金项目
编号:2014zy93 （）
